ASH: Axicabtagene Ciloleucel Slows Large B-Cell Lymphoma
Event-free survival prolonged with axi-cel versus standard care as second-line therapy for refractory, relapsed disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.